title: Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer.
abstract: Triple-negative breast cancer (TNBC) is not amenable to current targeted therapies and carries a poor prognosis; however, a specific systemic regimen cannot yet be recommended. The optimal duration of oxaliplatin (OXA) and S-1 combinatorial chemotherapy in patients with advanced breast cancer is not currently known and is likely to be patient-specific based on efficacy and toxicity. In the present study, 52 patients with advanced TNBC received OXA and S-1 chemotherapy. The efficacy and toxicity were observed. The results showed that the median number of regimens was 4 (range 2-6). The therapeutic efficacy was evaluated in all patients. The complete response, partial response, overall response and disease control rates were 3.8, 30.8, 34.6 and 69.2%, respectively. Four patients were lost to follow-up, and the median follow-up time was 13.7 months. The median progression-free survival time was 6.7 months [95% confidence interval (CI), 4.5-9.0] and the median overall survival (OS) time was 13.3 months (95% CI, 9.1-17.5). From the subgroup analysis, it was found that the median OS time of patients with stage IV disease and ≥2 metastases was significantly shorter than that of patients with stage IIIC disease and only 1 metastasis [11.3 vs. 22.7 months, P=0.010 (stage IV vs. stage IIC); 11.3 vs. 15.7 months, P=0.048 (≥2 vs. 1 metastasis)]. The main grade 3/4 toxic effects were neutropenia (11.5%), nausea (7.7%) and nerve toxicity (3.8%). The other toxic effects were mainly of grades 1-2 and included diarrhea, liver dysfunction, stomatitis, anemia and hand-foot syndrome. In conclusion, OXA combined with S-1 is an effective and tolerable regimen for the treatment of patients with advanced TNBC.
authors.affiliation: Department of Oncology, Taixing People's Hospital, Medical School of Yangzhou University, Taixing, Jiangsu 225400, P.R. China.
authors.forename: Jun
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Oncology, Taixing People's Hospital, Medical School of Yangzhou University, Taixing, Jiangsu 225400, P.R. China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Xiao
authors.affiliation: Department of Oncology, Taixing People's Hospital, Medical School of Yangzhou University, Taixing, Jiangsu 225400, P.R. China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.affiliation: Department of Oncology, Taixing People's Hospital, Medical School of Yangzhou University, Taixing, Jiangsu 225400, P.R. China.
authors.forename: Jian-Xiong
authors.initials: JX
authors.lastname: Guo
authors.affiliation: Department of Oncology, Taixing People's Hospital, Medical School of Yangzhou University, Taixing, Jiangsu 225400, P.R. China.
authors.forename: Yang-Chen
authors.initials: YC
authors.lastname: Liu
authors.affiliation: Department of Oncology, Taixing People's Hospital, Medical School of Yangzhou University, Taixing, Jiangsu 225400, P.R. China.
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Huang
authors.affiliation: Department of Oncology, Taixing People's Hospital, Medical School of Yangzhou University, Taixing, Jiangsu 225400, P.R. China.
authors.forename: Rong-Xia
authors.initials: RX
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Taixing People's Hospital, Medical School of Yangzhou University, Taixing, Jiangsu 225400, P.R. China.
authors.forename: Yi-Jia
authors.initials: YJ
authors.lastname: Wu
authors.affiliation: Department of Oncology, Taixing People's Hospital, Medical School of Yangzhou University, Taixing, Jiangsu 225400, P.R. China.
authors.forename: Juan
authors.initials: J
authors.lastname: Zhou
keywords: S-1; advanced triple-negative breast cancer; chemotherapy; oxaliplatin